Zobrazeno 1 - 10
of 184
pro vyhledávání: '"Elisabeth Ralfkiær"'
Publikováno v:
Frontiers in Medicine, Vol 3 (2016)
TP53 is frequently mutated in different types of neoplasms including leukemia and lymphomas. Mutations of TP53 have also been reported in mycosis fungoides (MF), the most common type of cutaneous lymphoma. However, little is known about the frequency
Externí odkaz:
https://doaj.org/article/05a6e7df5b6e4b8d84ff46d5141545d0
Autor:
Fazila Asmar, Vasu Punj, Jesper Christensen, Marianne T. Pedersen, Anja Pedersen, Anders B. Nielsen, Christoffer Hother, Ulrik Ralfkiaer, Peter Brown, Elisabeth Ralfkiaer, Kristian Helin, Kirsten Grønbæk
Publikováno v:
Haematologica, Vol 98, Iss 12 (2013)
The discovery that the Ten-Eleven Translocation (TET) hydroxylases cause DNA demethylation has fundamentally changed the notion of how DNA methylation is regulated. Clonal analysis of the hematopoetic stem cell compartment suggests that TET2 mutation
Externí odkaz:
https://doaj.org/article/ca73967b829e4a8091934e8a781b3ec1
Autor:
Kristian Helin, Guido Sauter, Mette Jørgensen, Jens Vilstrup Johansen, Henrik Holm Rossing, Elisabeth Ralfkiær, Ronald Simon, Eric Santoni-Rugiu, Heidi Rye Hudlebusch
Supplementary Figures S1-S4; Supplementary Tables S1-S3.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::77a2c5b1a9f2b4131d2caffc0bd78b75
https://doi.org/10.1158/1078-0432.22442583.v1
https://doi.org/10.1158/1078-0432.22442583.v1
Autor:
Kristian Helin, Guido Sauter, Mette Jørgensen, Jens Vilstrup Johansen, Henrik Holm Rossing, Elisabeth Ralfkiær, Ronald Simon, Eric Santoni-Rugiu, Heidi Rye Hudlebusch
Purpose: Multiple myeloma SET (Suppressor of variegation, Enhancer of zeste, and Trithorax) domain (MMSET) is a histone lysine methyltransferase deregulated in a subgroup of multiple myelomas with the t(4;14)(p16;q32) translocation and poor prognosis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::18fc12aec8de05e6c88e5490b9ed2612
https://doi.org/10.1158/1078-0432.c.6519273
https://doi.org/10.1158/1078-0432.c.6519273
Autor:
Elisabeth Ralfkiaer, Sirpa Leppä, Klaus Beiske, Harald Holte, Thomas Stauffer Larsen, Mats Jerkeman, Judit Jørgensen, Unn-Merete Fagerli, Martin Maisenhölder, Marja-Liisa Karjalainen-Lindsberg, Signe Spetalen, Magnus Björkholm, Leo Meriranta, Lars Munksgaard, Øystein Fluge, Ingunn Østlie, Peter de Nully Brown, Knut Liestøl, Anne Tierens, Susanna Mannisto, Kaija Vasala, Sirkku Jyrkkiö, Peter Meyer
Publikováno v:
Leppä, S, Jørgensen, J, Tierens, A, Meriranta, L, Østlie, I, de Nully Brown, P, Fagerli, U M, Larsen, T S, Mannisto, S, Munksgaard, L, Maisenhölder, M, Vasala, K, Meyer, P, Jerkeman, M, Björkholm, M, Fluge, Ø, Jyrkkiö, S, Liestøl, K, Ralfkiaer, E, Spetalen, S, Beiske, K, Karjalainen-Lindsberg, M L & Holte, H 2020, ' Patients with high-risk DLBCL benefit from dose-dense immunochemotherapy combined with early systemic CNS prophylaxis ', Blood advances, vol. 4, no. 9, pp. 1906-1915 . https://doi.org/10.1182/bloodadvances.2020001518
Leppä, S, Jørgensen, J, Tierens, A, Meriranta, L, Østlie, I, de Nully Brown, P, Fagerli, U-M, Larsen, T S, Mannisto, S, Munksgaard, L, Maisenhölder, M, Vasala, K, Meyer, P, Jerkeman, M, Björkholm, M, Fluge, Ø, Jyrkkiö, S, Liestøl, K, Ralfkiaer, E, Spetalen, S, Beiske, K, Karjalainen-Lindsberg, M-L & Holte, H 2020, ' Patients with high-risk DLBCL benefit from dose-dense immunochemotherapy combined with early systemic CNS prophylaxis ', Blood Advances, vol. 4, no. 9, pp. 1906-1915 . https://doi.org/10.1182/bloodadvances.2020001518
Blood Advances
Blood Adv
Leppä, S, Jørgensen, J, Tierens, A, Meriranta, L, Østlie, I, de Nully Brown, P, Fagerli, U-M, Larsen, T S, Mannisto, S, Munksgaard, L, Maisenhölder, M, Vasala, K, Meyer, P, Jerkeman, M, Björkholm, M, Fluge, Ø, Jyrkkiö, S, Liestøl, K, Ralfkiaer, E, Spetalen, S, Beiske, K, Karjalainen-Lindsberg, M-L & Holte, H 2020, ' Patients with high-risk DLBCL benefit from dose-dense immunochemotherapy combined with early systemic CNS prophylaxis ', Blood advances, vol. 4, no. 9, pp. 1906-1915 . https://doi.org/10.1182/bloodadvances.2020001518
Leppä, S, Jørgensen, J, Tierens, A, Meriranta, L, Østlie, I, de Nully Brown, P, Fagerli, U-M, Larsen, T S, Mannisto, S, Munksgaard, L, Maisenhölder, M, Vasala, K, Meyer, P, Jerkeman, M, Björkholm, M, Fluge, Ø, Jyrkkiö, S, Liestøl, K, Ralfkiaer, E, Spetalen, S, Beiske, K, Karjalainen-Lindsberg, M-L & Holte, H 2020, ' Patients with high-risk DLBCL benefit from dose-dense immunochemotherapy combined with early systemic CNS prophylaxis ', Blood Advances, vol. 4, no. 9, pp. 1906-1915 . https://doi.org/10.1182/bloodadvances.2020001518
Blood Advances
Blood Adv
Leppä, S, Jørgensen, J, Tierens, A, Meriranta, L, Østlie, I, de Nully Brown, P, Fagerli, U-M, Larsen, T S, Mannisto, S, Munksgaard, L, Maisenhölder, M, Vasala, K, Meyer, P, Jerkeman, M, Björkholm, M, Fluge, Ø, Jyrkkiö, S, Liestøl, K, Ralfkiaer, E, Spetalen, S, Beiske, K, Karjalainen-Lindsberg, M-L & Holte, H 2020, ' Patients with high-risk DLBCL benefit from dose-dense immunochemotherapy combined with early systemic CNS prophylaxis ', Blood advances, vol. 4, no. 9, pp. 1906-1915 . https://doi.org/10.1182/bloodadvances.2020001518
Survival of patients with high-risk diffuse large B-cell lymphoma (DLBCL) is suboptimal, and the risk of central nervous system (CNS) progression is relatively high. We conducted a phase 2 trial in 139 patients aged 18 to 64 years who had primary DLB
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3b8a880a8202aaafba6bd8012e2cb53b
https://findresearcher.sdu.dk:8443/ws/files/170252025/advancesadv2020001518.pdf
https://findresearcher.sdu.dk:8443/ws/files/170252025/advancesadv2020001518.pdf
Autor:
Elisabeth Ralfkiaer, Konstantinos Dimopoulos, Peter Gimsing, Helga Fibiger Munch-Petersen, Christian Winther Eskelund, Kirsten Grønbæk, Lene Dissing Sjö
Publikováno v:
Leukemia & Lymphoma. 60:180-188
The immunomodulatory drug thalidomide, and its analogs, lenalidomide, and pomalidomide (IMiDs), have become essential components of the standard treatment for multiple myeloma (MM), and have led to significant improvement of survival in patients with
Autor:
Dorte Tholstrup, Jakob Werner Hansen, Eileen Wedge, Christian Garde, Fazila Asmar, Elisabeth Ralfkiaer, Søren Sommer Kristensen, Peter de Nully Brown, Kirsten Grønbæk, Helga D. Munch-Petersen, Lasse Sommer Kristensen
Publikováno v:
American Journal of Hematology. 92:689-694
Global hypomethylation has been linked to disease progression in several cancers, but has not been reported for Diffuse Large B Cell Lymphoma (DLBCL). This study aimed to assess global methylation in DLBCL and describe its prognostic value. Mean LINE
Autor:
Niki Stavroyianni, Helga D. Munch-Petersen, Kenichi Yoshida, Markus Schneider, Andreas Rosenwald, German Ott, Lucile Couronné, Michael Hummel, Marita Ziepert, Daniel Noerenberg, Emma Young, Richard Rosenquist, Seishi Ogawa, Thorsten Zenz, Jonathan C. Strefford, Larry Mansouri, Rose-Marie Amini, Hans G. Drexler, Viktor Ljungström, Martin-Leo Hansmann, Mareike Frick, Dido Lenze, Martin Erlanson, Ralf Küppers, Alfredo Rivas-Delgado, Armando López-Guillermo, Elisabeth Ralfkiaer, Christopher Maximilian Arends, Magnus Hultdin, Tatjana Pandzic, Bernd Dörken, Claudia D. Baldus, Maria K. Angelopoulou, Theodora Papadaki, Kirsten Grønbæk, Kostas Stamatopoulos, Anna Tasidou, Maysaa Abdulla, Nils Waldhueter, Frederik Damm, Theodoros P. Vassilakopoulos, Elias Campo, Damien Roos-Weil, Jude Fitzgibbon, Elena Mylonas, Blanca Gonzalez, Penelope Korkolopoulou, George Kanellis, Aron Skaftason, Gunilla Enblad, Olivier A. Bernard, Fazila Asmar, Jessica Okosun, Clemens A. Schmitt, Christian Bastard
Publikováno v:
Blood. 128:2666-2670
We recently reported a truncating deletion in the NFKBIE gene, which encodes IκBε, a negative feedback regulator of NF-κB, in clinically aggressive chronic lymphocytic leukemia (CLL). Because preliminary data indicate enrichment of NFKBIE aberrati
Autor:
Hans Carl Hasselbalch, Karsten Nielsen, Helle Charlotte Knudsen, Ann Brinch Madelung, Preben Løvgreen, Jürgen Thiele, Anne Falensteen, Henrik Bondo, Kira Dynnes Svendsen, Elisabeth Ralfkiaer, Signe Ledou Nielsen, Theis Lange, Inger Stamp
Publikováno v:
APMIS. 123:787-792
We examined the learning effect of a workshop for Danish hematopathologists led by an international expert regarding histological subtyping of myeloproliferative neoplasms (MPN). Six hematopathologists evaluated 43 bone marrow (BM) biopsies according
Autor:
Mariusz A. Wasik, Lars Jønson, Charlotte M. Bonefeld, Lise Mette Rahbek Gjerdrum, Elisabeth Ralfkiaer, Niels Ødum, Ulrik Ralfkiaer, Anders Woetmann, Katharina L. Kopp, Carsten Geisler, Qian Zhang, Sally Dabelsteen, Louise Christensen, Britt Lauenborg
Publikováno v:
Oncotarget
Europe PubMed Central
Scopus-Elsevier
Europe PubMed Central
Scopus-Elsevier
// Britt Lauenborg 1 , Louise Christensen 1 , Ulrik Ralfkiaer 2 , Katharina L. Kopp 1 , Lars Jonson 3 , Sally Dabelsteen 4 , Charlotte M. Bonefeld 1 , Carsten Geisler 1 , Lise Mette R. Gjerdrum 5 , Qian Zhang 6 , Mariusz A. Wasik 6 , Elisabeth Ralfki